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Abstract
A response to and comment on The BRAIN TRIAL: a randomised, placebo controlled trial
of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain
injury, by Haleema Shakur, Ian Roberts, et al.
Letter
Ommisions and inaccuracies
As stated in the BRAIN TRIAL manuscript [1], Xytis was
the financial Sponsor of this clinical trial, during the
course of which there were substantive disagreements
between the Sponsor and LSHTM. As pointed out in the
manuscript, the Trial was interrupted due to safety con-
cerns on 1 November, 2007 based on an un-blinded anal-
ysis of the data to that point by the DSMB.
The BRAIN TRIAL manuscript clearly states the definition
of a Serious Adverse Event. What is not said is that in this
clinical trial, LSHTM used two versions of SAEs. The first
version was a completed CRF (absent an SAE form) in
which the investigator ticked the box indicating that an
adverse event was serious, but did not fill out the SAE
form, which is a regulatory requirement for an SAE. A sep-
arate entity, HPM, had responsibility for reporting SAEs
(that is the real SAEs on SAE forms) to Xytis and to the
appropriate regulatory authorities. Investigators ticked
about twice as many Adverse Events, Serious boxes as they
filled out SAE forms. While the BRAIN TRIAL manuscript
treats SAEs as always being a unique population, in fact
the reconciliation of Adverse Events, Serious with real
SAEs reported to HPM was not accomplished until May of
2008, despite the fact that LSHTM received the SAE forms
from the investigators and forwarded them to HPM. As of
1 November, fully 56.4% (54 out of 94) of the Adverse
Events, Serious reported to the DSMB were actually
adverse events that were not Serious Adverse Events
according to the protocol (as subsequently reported by
LSHTM). In fact, at the time the trial was stopped, HPM
had received only 49 SAEs, and as required, had reported
these to regulatory authorities. Thus the decision by the
DSMB to interrupt the trial was based on mostly (56.4%)
erroneous information. The failure of LSHTM to "clean"
the database in a timely manner was a direct cause of the
excessive accumulation of Adverse Events, Serious.
The Manuscript inaccurately states the Study Objectives,
which were defined by the protocol as a Primary Objective
"to evaluate the safety of different doses of XY2405 when
used as a treatment for acute TBI in order to inform dose
selection for a phase III trial" and a Secondary Objective
"to assess the effect of XY2405 on mortality, morbidity
among patients with acute TBI".
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Xytis' concern is that the BRAIN TRIAL manuscript is
biased. For example while the authors performed both Per
Protocol and Intent to Treat analyses, the authors selec-
tively chose data from one or the other for presentation.
Another example of bias is when the authors state "It is
unknown to the authors whether the decision to with-
draw funding was influenced by the unscheduled un-
blinded analyses", is patently false. It is well known by the
LSHTM authors that Xytis formally requested termination
of the trial in mid-November, long before Xytis had access
to un-blinded data.
In terms of un-blinding, it should be noted that I was the
only Xytis employee who had access to un-blinded data,
and I was not involved in the conduct of the trial or the
analysis of the data, which was under the control of
LSHTM. However, several LSHTM employees who had
direct involvement in the trial (Haleema Shakur and Ian
Roberts) reviewed un-blinded data while queries were
ongoing and prior to the final data analysis. The impact of
these un-blindings on their analysis is not known.
The HIREOS scale has not been published, and as such
may be a source of bias.
Additional Analysis of the Data from the BRAIN TRIAL
Table 1 below indicates the deaths of patients versus their
initial or entry GCS score and their treatment (placebo,
low, medium or high dose XY2405).
It is apparent that deaths are about even among the four
treatment arms. What is striking however, is the death rate
among the three GCS cohorts. One would have expected
that patients with GCS scores of 3, 4 and 5 would have
suffered the highest death rate. The average of this group
was 16% mortality. The average of the next highest cohort
of GCS entries (GCS 6 - 8) was 32%, twice that of the sup-
posedly more severe traumatic brain injury cohort. This is
a most unexpected result. A careful review of the protocol
as well as the training instructions given to investigators
indicates that no policy or procedures were established to
assure that a consistent initial GCS was taken. The nature
of TBI is that many patients, particularly those with poly-
trauma, are partially or completely sedated, on ventila-
tors, etc., and assessment of their initial GCS score can
vary considerably over a few hours. Strict criteria are
needed to ensure that all clinical sites use the same criteria
for the entry GCS score. The data from the BRAIN TRIAL
clearly indicates that the initial GCS score is not reliable in
this trial. Inasmuch as the authors "adjusted" the data,
including the DRS and HIREOS, to take into account the
entry GCS scores, their entire analysis is flawed.
In my opinion, the BRAIN TRIAL manuscript is both
biased and flawed, and cannot be relied upon as a reliable
presentation of the data from this clinical trial.
Abbreviations
DRS: Disability Rating Scale; DSMB: Data Safety Monitor-
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Table 1: GCS score compared with the number of deaths in each treatment group, as well as the total deaths for each GCS group.
GCS Placebo Low Medium High Total Deaths Deaths/patient treated by cohort
33 0 0 3 6 1 6 %
40 0 0 1 1
51 1 1 0 3
62 7 3 0 1 2 3 2 %
70 1 3 2 6
83 0 1 0 4
92 0 2 2 6 1 5 %
10 0 0 1 1 2
11 0 0 0 0 2
12 0 1 1 1 3
Total Deaths 11 10 12 12 45
The three cohorts (GCS 3-5, GCS 6-8, and GCS 9-12) are the same cohorts used in the BRAIN TRIAL to achieve balance among treatment groups.Publish with BioMed Central    and   every 
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Injury Related Early Outcome Score; LSHTM: London
School of Hygiene and Tropical Medicine; NIH: National
Institutes of Health; HPM: Healthcare Project Manage-
ment, Geneva; CRF: Case report form.
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